Hangzhou Alltest Biotech (688606.SH) released a pre-increase forecast, with an expected net profit of 278 million to 298 million yuan in 2024, a year-on-year increase of 53.95% to 65.03%.
OCT Biotech (688606.SH) announced that the company is expected to achieve a net profit attributable to the parent company for the year 2024...
Hangzhou Alltest Biotech (688606.SH) announced that the company is expected to achieve a net profit attributable to owners of the parent company of 278-298 million yuan in 2024, compared to the same period last year (statutory disclosure data), an increase of 97.4238-117.4238 million yuan, a year-on-year increase of 53.95% to 65.03%.
During the reporting period, the company continued to focus on the POCT sub-sector of the in vitro diagnostics industry, effectively grasping market demand, continuously promoting product and service innovation, deepening market expansion strategies. At the same time, the company strengthened internal refined management, improved operational efficiency and cost control capabilities, and took multiple measures to jointly promote steady growth in performance.
Related Articles

GUOTAI JUNAN I: Why are gold and US Treasury bonds rising together amid the frenzy of "depreciation trading" in the US dollar?

SINO BIOPHARM (01177): The study data of the first-line treatment of advanced stage III breast cancer with the combination of Comorsi and Fluvisq was announced at ESMO 2025.

HK Bull/Bear Outstanding Qty Ratio(59:41) | October 21st
GUOTAI JUNAN I: Why are gold and US Treasury bonds rising together amid the frenzy of "depreciation trading" in the US dollar?

SINO BIOPHARM (01177): The study data of the first-line treatment of advanced stage III breast cancer with the combination of Comorsi and Fluvisq was announced at ESMO 2025.

HK Bull/Bear Outstanding Qty Ratio(59:41) | October 21st

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025